Document 0360
 DOCN  M9590360
 TI    Multiple opportunistic pathogen prophylaxis (MOPP): an overview.
 DT    9509
 AU    Jacobson MA; University of California, San Francisco, USA.
 SO    Annu Conf Australas Soc HIV Med. 1994 Nov 3-6;6:133 (unnumbered
       abstract). Unique Identifier : AIDSLINE ASHM6/95291739
 AB    Patients with CD4 counts < 100 are at risk for multiple AIDS-defining
       opportunistic infections (OI's), especially PCP, disseminated MAC, CMV
       end-organ disease, and systemic fungal infection. There is now
       convincing evidence from randomized, controlled trials that
       administration of specific agents can decrease the incidence of each of
       these target OI's. TMP-SMX, dapsone and aerosolized pentamidine each can
       decrease the risk of developing PCP, rifabutin (RIFB) can decrease MAC,
       fluconazole (FCZ) can decrease cryptococcosis, and oral ganciclovir
       (GCV) can decrease CMV disease. Although there is convincing evidence
       from natural history studies that PCP prophylaxis prolongs survival, it
       is unclear whether administration of additional prophylactic agents
       targeting other OI's improves either survival or quality of life in
       patients with advanced HIV disease. In addition, potential undesirable
       drug interactions may occur with certain MOPP and antiretroviral drug
       combinations (e.g. TMP-SMX or dapsone with RIFB, FCZ with RIFB, GCV with
       AZT or TMP-SMX, dapsone with ddI). Prospective trials evaluating MOPP
       regimens are needed to determine their clinical utility.
 DE    Anti-Infective Agents/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
       AIDS-Related Opportunistic Infections/IMMUNOLOGY/MORTALITY/  *PREVENTION
       & CONTROL  CD4 Lymphocyte Count  Drug Interactions  Drug Therapy,
       Combination  Human  Quality of Life  Survival Rate  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).